CD53 and acute lymphoblastic leukemia: Analogous to the paradigm of non-cross-resistant cytotoxic chemotherapy regimens required to achieve cure in patients with ALL, we aimed in this preclinical study to co-attack essential CRLF2/TSLPR biology in Ph-like and DS-ALL via (1) unique cell surface antigen-targeted CAR T cell immunotherapy and (2) intracellular constitutive signaling-targeted tyrosine kinase inhibition.